• Home
  • »
  • About Alexion

About Alexion

Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies.

Since its founding in 1992, Alexion has given hope to people who had none and shined a light on those who felt isolated and alone. But we know that fighting rare diseases takes so much more than hope. It requires persistence, dedication, and a relentless pursuit of the highest levels of medical innovation. At Alexion, our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives are at stake.

Alexion has 2,500 passionate and dedicated employees serving patients in 50 countries around the world.

Our breakthrough Therapies

Through the transformative power of our science, Alexion has delivered life-changing therapies to patients suffering from rare diseases. We have pioneered the complex field of complement biology and delivered solutions to challenges that once seemed impossible for patients with devastating complement-mediated and metabolic disorders.

Alexion developed Soliris® (eculizumab), the world's first approved terminal complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG).

Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders—Strensiq® (asfotase alfa) for patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D).

Our Future

Alexion’s ambition is to be the global leader in rare diseases. By leveraging our 20+ years of expertise in complement biology and our capabilities in hematology, nephrology, neurology, and metabolic disorders, we will bring additional life-changing therapies to patients and redefine what it means to live with a rare disease. Our legacy will be measured in the families we serve today and the generations that follow.